Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity

' This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations. 'MDedge News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news